Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Sign Up to like & getrecommendations! Published in 2019 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2019.114657
Abstract: CD3 bispecific constructs show promising therapeutic potential as anti-tumor antibodies, but it has concurrently been difficult to manage cytokine release syndrome (CRS) in clinical use. Currently, the most effective measure for reducing CRS is considered… read more here.
Keywords: daily ascending; cynomolgus monkeys; release syndrome; cytokine release ... See more keywords